Suven Life Sciences Limited Total Liabilities
Suven Life Sciences Limited total liabilities. Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has total liabilities worth Rs561.36 Million INR (≈ $6.07 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SUVEN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Suven Life Sciences Limited (2005–2025)
Total liabilities of Suven Life Sciences Limited from 2005 to 2025. This chart illustrates how Suven Life Sciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Suven Life Sciences Limited's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Suven Life Sciences Limited Competitors by Total Liabilities
The table below lists competitors of Suven Life Sciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kirloskar Ferrous Industries Limited
NSE:KIRLFER
|
India | Rs-38.63 Billion |
|
Zhongzhong Science & Technology (Tianjin) Co. Ltd. A
SHG:603135
|
China | CN¥868.79 Million |
|
B Communications Ltd
TA:BCOM
|
Israel | ILA13.27 Billion |
|
Yijiahe Technology Co Ltd
SHG:603666
|
China | CN¥1.06 Billion |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
China | CN¥940.80 Million |
|
Cresud SA
BA:CRES
|
Argentina | AR$3.71 Trillion |
|
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
|
China | CN¥2.19 Billion |
|
Xinyaqiang Silicon Chemistry Co Ltd
SHG:603155
|
China | CN¥260.21 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Suven Life Sciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SUVEN asset base.
Liquidity & Leverage Metrics
Suven Life Sciences Limited Total Liabilities Ratios Explained
Suven Life Sciences Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Suven Life Sciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Suven Life Sciences Limited (2005–2025)
The table below shows the annual total liabilities of Suven Life Sciences Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs251.97 Million ≈ $2.72 Million |
+69.54% |
| 2024-03-31 | Rs148.62 Million ≈ $1.61 Million |
+9.35% |
| 2023-03-31 | Rs135.91 Million ≈ $1.47 Million |
+14.32% |
| 2022-03-31 | Rs118.89 Million ≈ $1.29 Million |
-41.75% |
| 2021-03-31 | Rs204.12 Million ≈ $2.21 Million |
-47.10% |
| 2020-03-31 | Rs385.84 Million ≈ $4.17 Million |
-81.44% |
| 2019-03-31 | Rs2.08 Billion ≈ $22.48 Million |
+42.28% |
| 2018-03-31 | Rs1.46 Billion ≈ $15.80 Million |
-1.74% |
| 2017-03-31 | Rs1.49 Billion ≈ $16.08 Million |
-21.80% |
| 2016-03-31 | Rs1.90 Billion ≈ $20.57 Million |
-11.06% |
| 2015-03-31 | Rs2.14 Billion ≈ $23.12 Million |
-3.76% |
| 2014-03-31 | Rs2.22 Billion ≈ $24.03 Million |
+23.66% |
| 2013-03-31 | Rs1.80 Billion ≈ $19.43 Million |
+14.10% |
| 2012-03-31 | Rs1.57 Billion ≈ $17.03 Million |
+62.51% |
| 2011-03-31 | Rs968.96 Million ≈ $10.48 Million |
+11.77% |
| 2010-03-31 | Rs866.89 Million ≈ $9.38 Million |
+20.90% |
| 2009-03-31 | Rs717.02 Million ≈ $7.75 Million |
-22.18% |
| 2008-03-31 | Rs921.44 Million ≈ $9.96 Million |
+28.47% |
| 2007-03-31 | Rs717.22 Million ≈ $7.76 Million |
+35.80% |
| 2006-03-31 | Rs528.14 Million ≈ $5.71 Million |
-3.25% |
| 2005-03-31 | Rs545.88 Million ≈ $5.90 Million |
-- |
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more